Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Financial Statements and Exhibits

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Financial Statements and Exhibits
Item 9.01.

 
 
Story continues below

PROGENICS PHARMACEUTICALS INC Exhibit
EX-10.1 2 ex_177368.htm EXHIBIT 10.1 ex_177368.htm Exhibit 10.1     Execution Version         BRIDGE LOAN AGREEMENT   dated as of March 15,…
To view the full exhibit click here

About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.

An ad to help with our costs